
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of ALPS Medical Breakthroughs ETF (ARCA:SBIO) through any online brokerage.
There are no as such competitors for ALPS Medical Breakthroughs ETF.
There is no analysis for ALPS Medical Breakthroughs ETF to provide a consensus price target.
The stock price for ALPS Medical Breakthroughs ETF (ARCA: SBIO) is $ last updated .
There are no upcoming dividends for ALPS Medical Breakthroughs ETF.
ALPS Medical Breakthroughs ETF does not have any upcoming earnings scheduled.
There is no upcoming split for ALPS Medical Breakthroughs ETF.
| Sector | Healthcare |
| Category | High Performer-High Growth |
| Investment Style | Small Cap Growth |
| Fund Inception | Dec 30, 2014 |
| Managers | Ryan Mischke Charles Perkins |
| Definition | An equity fund portfolio full of stocks with both strong financial performance and superior growth potential |
| Symbol | Name | Share % |
|---|---|---|
| KYMR | Kymera Therapeutics In... | 3.82% |
| CELC | Celcuity Inc Common St... | 3.21% |
| IE | Alkermes Plc | 3.09% |
| CRNX | Crinetics Pharmaceutic... | 3.06% |
| ACAD | Acadia Pharmaceuticals... | 2.96% |
| FOLD | Amicus Therapeutics In... | 2.94% |
| APGE | Allogene Therapeutics ... | 2.84% |
| MIRM | Mirum Pharmaceuticals ... | 2.59% |
| GPCR | Structure Therapeutics... | 2.55% |
| NAMS | Newamsterdam Pharma Co... | 2.54% |